We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

3 hedge funds and large institutions have $262K invested in XTL Biopharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $224K → $262K (+$38K)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$1K
2
TRCT
Tower Research Capital (TRC)
New York
-$261
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$257K – – –
UBS Group
2
UBS Group
Switzerland
$3K +$3.44K +79 New
TRCT
3
Tower Research Capital (TRC)
New York
$2K -$261 -6 -11%
Ameriprise
4
Ameriprise
Minnesota
– -$1K -22 Closed

XTLB Hedge Fund Activity: Q4 2014 in Review

3 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2014, worth a combined $262K — up 17% from $224K a quarter earlier.

Fund positioning in XTLB was balanced in Q4 2014: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Ameriprise, exiting entirely with an estimated $1K sold.

  • 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $262K of XTL Biopharmaceuticals stock for Q4 2014, up 17% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q4 2014 and 1 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals seller in Q4 2014 was Ameriprise, an estimated $1K sold.

Based on aggregated 13F filings for Q4 2014.